Clinical Evidence
Study Two
Efficacy of Gelclair® in reducing pain in patients with oral lesions − preliminary findings from an open pilot study
Innocenti M, Moscatelli G, Lopez S.
Pain Symptom Manage 2002; 24(5): 456−457.
Patients' Response
Study Outline
Thirty patients with painful lesions of the mouth and oropharynx (caused by various diseases) were evaluated for short term (5−7 hours) and medium term (7−10 days) effects of Gelclair® on the severity of pain on swallowing and eating.
Results
The significant reduction was observed with the short term not medium term. The results are encouraging but not conclusive. In this 10 day trial, results indicated that Gelclair® rapidly and effectively reduces pain associated with oral lesions (e.g. oral mucositis), and can improve ability to eat and drink, with continued use.
Reporting of side effects
Medical device adverse incidents should be reported to the MHRA. Reporting information can be found at https://yellowcard.mhra.gov.uk/. Any adverse event should also be reported to Pharmacovigilance at Alliance Pharmaceuticals Limited
Tel: 01249 466 966 or email: [email protected]
